Johnson & Johnson “most valuable” pharma brand, says report
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
List view / Grid view
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
Drug shortages can greatly impact patients and the pharmaceutical industry. Adrian van den Hoven, Director General of Medicines for Europe, explains how to prevent and reduce the effects of medicinal scarcities in the EU.
Experts in the UK have called for government action to resolve the shortages of hormone replacement therapy and now contraceptives.
7 February 2020 | By OSIsoft
Trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Hear the latest findings from OSIsoft’s research in our on-demand webinar.
Mavidon has recalled LemonPrep, PediaPrep, Wave Prep and Cardio Prep due to the products being potentially contaminated with Burkholderia cepacia.
Medreich Plc is recalling a number of ranitidine products due to possible contamination with an impurity N-nitrosodimethylamine (NDMA).
The EU Medical Devices Regulation will apply in May 2020. Maurits Lugard and Josefine Sommer of Sidley Austin LLP examine what the changes mean for the medtech industry.
The US NIAID has stopped its HVTN 702 clinical trial for an HIV vaccine after an independent board found that the treatment did not prevent the condition.
Rompe Pecho EX, Rompe Pecho CF and Rompe Pecho MAXliquid are being recalled due to microbial contamination.
Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.
The EMA has released a statement, outlining the future for the UK's pharmaceutical industry in the transition period following Brexit and thereafter.
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
Due to a notification of the impurity, liothyronine, exceeding the specification limit, certain batches of levothyroxine 100micrograms/5ml oral solution are being recalled.
Based on a study of the pharma industry’s remediation projects, this white paper from NSF looks at the key issues behind GMP non-conformance. It also includes questions to ask yourself when making changes to your processes and systems.
KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.